Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)
Press Release
November 4, 2021
Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today that updated results from the company’s ongoing ADVANCE II study with Immunicum’s cancer relapse vaccine DCP-001 will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021.
The ADVANCE II study is an international, multi-center, open label Phase II study in which two different dosing regimens of DCP-001 are studied in acute myeloid leukemia patients with persistent measurable residual disease (MRD).
“Initial results from the ADVANCE II study reported to date demonstrated that treatment with DCP-001 was safe, well tolerated and showed promising early signs of efficacy on converting patients to an MRD negative status,” commented Jeroen Rovers, M.D., Ph.D., Chief Medical Officer at Immunicum. “We look forward to sharing more mature data from the fully enrolled clinical study with the scientific and medical community at the ASH conference this year.”
Accepted abstracts will be available online on the ASH website on November 4th from 9:00 AM Eastern Daylight Time (EDT) 2:00 PM Central European Time (CET): https://www.hematology.org/meetings/annual-meeting/abstracts
Poster Details:
Poster Title: Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival
Presenter: Arjan Van de Loosdrecht, Ph.D,
Abstract Number: 1274
Session Title: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
Session Date & Time: Saturday, December 11, 2021, 5:30 PM - 7:30 PM EST
Location: Georgia World Congress Center, Hall B5
All posters will be made available as virtual ePosters throughout the 63rd ASH Annual Meeting. In addition, the poster will be made available on the Immunicum website following the poster presentation.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Brendan Payne
Stern Investor Relations
Telephone: +1 212-698-8695
E-mail: brendan.payne@sternir.com
For Sweden:
Kristina Windrup Olander
Spikinc AB
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
MEDIA RELATIONS
Eva Mulder and Sophia Hergenhan
Trophic Communications
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu
About Immunicum AB (publ)
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.
www.immunicum.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Connecterra and Lely Announce Strategic Partnership2.12.2021 15:05:00 CET | Press release
Following the completion of a successful pilot, the two companies will deepen their collaboration and commercial relationship Amsterdam, The Netherlands, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Today Dutch-based startup, Connecterra, a world leader in using artificial intelligence to deliver insights to farmers, and Lely, the global leading supplier of robotics and management systems for dairy farming, announced the start of a robust co-development and commercial partnership. The announcement follows a pilot with Lely’s Digital Farming Group. The pilot program was designed to test an integration between Lely Horizon and Connecterra’s artificial intelligence platform, Ida. The successful effort has resulted in commitments to several strategic initiatives. As a first step in the agreement, Lely will now license Ida Enterprise for use in their farm management system Lely Horizon. “We believe that digitization of dairy farming is key and needs to be handled with care. Integrating with partners l
Fobi Announces Signing Of Amazon Fulfillment And Business Seller Agreement2.12.2021 13:45:00 CET | Press release
Fobi’s hardware and software solutions will now be available on Amazon Business, reaching over five million businesses worldwide VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. Inc.(FOBI:TSXV FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, announced it has signed an agreement with Amazon for distribution and fulfillment of Fobi AI’s various hardware products. As part of the agreement, Fobi will also become an Amazon Business Seller which will enable Fobi to gain access to Amazon’s global e-commerce, logistics and fulfillment infrastructure. By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now be included in. Fobi will now generate additional revenue through hardware, products and services sold on Amazon Business. Fobi will be launching their Fobi 3.0 I
Mandalay Resources Corporation Completes Sale of Cerro Bayo Mine to Equus Mining2.12.2021 13:30:00 CET | Press release
TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce that it has completed the previously announced sale of its Cerro Bayo mine in Region XI, Southern Chile (see Mandalay press releases dated October 12, 2021, and October 8, 2019). Pursuant to the transaction, Equus Mining Limited (“Equus”) acquired the Cerro Bayo mine, including its mining properties, resources and mine infrastructure as well as a 1,500 tonnes per day processing plant, in exchange for 587,502,438 ordinary shares in the capital of Equus. Mandalay also retains a 2.25% net smelter royalty on production from the Cerro Bayo mining claims once the mine has produced at least 50,000 ounces of gold equivalent, subject to a re-purchase option in favour of Equus, and remains responsible for 50% of approved site closure costs at Cerro Bayo. In addition, Equus will appoint Ryan Austerberry, Mandalay’s Costerfield mine General Manager
CTG and Micro Focus Extend European Platinum Partnership to French Market2.12.2021 12:55:00 CET | Press release
PARIS, Dec. 02, 2021 (GLOBE NEWSWIRE) -- CTG (NASDAQ: CTG), a leading provider of digital IT services and solutions in North America and Western Europe, today announced an expanded strategic partnership agreement with Micro Focus to now include CTG France. The partnership aligns CTG’s testing capabilities with Micro Focus’ Application Lifecycle Management (ALM) software to help clients accelerate their software delivery and ensure quality and application performance at every stage of the digital application lifecycle. Leveraging the global organization’s decades of experience, a team of more than 500 testers, and a network of more than 3,000 crowdtesters, CTG France offers its clients comprehensive Application Testing Solutions. The Company’s Testing Solutions portfolio includes advisory consulting, test methodology and process, performance testing, manual functional testing, testing automation, test tool implementation, and crowdtesting. Many of CTG’s more than 400 clients use Micro F
WESTPAY AND EASYCASHIER COMPLETE SUCCESSFUL LAUNCH OF MULTI-USER PAYMENT SOLUTION2.12.2021 12:45:00 CET | Press release
Westpay AB, a leading fintech company, has enabled multi-user functionality (MultiTID) in their payment application. This solution makes it possible for several users to share a physical payment solution. This is in demand in several verticals, such as hairdressers, who share premises but run their business individually. EasyCashier, a leading POS provider and a close partner to Westpay will be the first partner that offer this solution for their customers. - Again, I am proud that Westpay continues to push the limits to what you can expect from a payment solution.We have seen this functionality before, but the way we manage to simplify the use of sharing payment solutions. It is also happy that EasyCashier embraces this solution and enables it for their customers. They are a solid, reliable partner with great expertise and experience, says Hans Edin, CCO at Westpay. - Quality and innovation are two vital features for us at EasyCashier. We always try to level up the value as well as th
TGS Share Repurchase2.12.2021 10:57:49 CET | Press release
Oslo, Norway (02 December 2021) – On period from 25 November 2021 to 01 December 2021, TGS ASA (TGS) purchased 67,328 own shares on the Oslo Stock Exchange at an average price of NOK 85.1890 per share. Following the purchase TGS owns 1,226,303 shares, representing 1.044% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)25-Nov-2110,87888.9977968,11726-Nov-2120,00084.97931,699,58629-Nov-212,00084.2400168,48030-Nov-2120,00084.16361,683,2721-Dec-2114,45084.16241,216,147Previously disclosed buy-backs under the program (accumulated)1,143,975105.5774120,777,940Accumulated under the buy-back program1,211,303104.4442126,513,541The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,226,303 own shares, corresponding to
AB Linas Agro Group investors calendar for the 20222.12.2021 10:41:10 CET | Press release
A list of key information disclosure dates in 2022: February 28, 2022Interim half-year unaudited report for FY 2021/2022.March 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2021/2022.May 31, 2022Interim unaudited report for 9 months of FY 2021/2022.June 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2021/2022.August 31, 2022Interim unaudited report for 12 months of FY 2021/2022.September 2, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2021/2022.Week 40 (Oct 3-7, 2022)Notice on Annual General Meeting of shareholders.Week 43 (Oct 24-28, 2022) Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2021/2022.November 30, 2022Interim unaudited report for 3 months of 2022/2023 financial year.December 1, 2022Investor Conference Webinar to introduce unaudited financial an